Three and a half weeks after the Justice Department moved state-licensed medical cannabis to Schedule III, a cluster of practical consequences is landing simultaneously. Federal agencies are updating registration requirements and legal forms, the industry is calculating the limits of advertising relief, and one of the sector’s largest publicly listed operators has reported its strongest-ever first quarter. Separately, a Massachusetts bid to roll back the state’s adult-use market has hit a legislative wall.

Cronos posts record first-quarter revenue driven by Israel and international growth

Cronos Group reported first-quarter 2026 net revenue of $45.2 million, a 40 per cent increase year on year, alongside net income of $15.7 million, according to a results announcement on GlobeNewsWire. The Israeli operation delivered a 53 per cent revenue increase, while international markets outside Israel grew 97 per cent to record levels. The Spinach® brand captured the top position in Canadian vapes for the first time. Chief executive Mike Gorenstein cited a “clear and focused growth strategy” as the company carries $822 million in cash and activates a $50 million share repurchase programme. Track Cronos alongside other public operators on the Business of Cannabis stocks tracker.

Rescheduling frees cannabis marketing budgets but Big Tech ad gates stay closed

Federal rescheduling to Schedule III does not unlock advertising on Google, Meta or other major technology platforms, according to MJBizDaily. Those companies are conditioning any policy shift on full adult-use legalisation rather than the current medical-only order. The more immediate benefit is indirect: 280E tax relief means operators will have additional cash to direct towards brand-building, sponsorships and events—promotional channels that were crowded out by the sector’s historically punitive tax burden. The Food and Drug Administration will continue to monitor and act on medical and therapeutic claims, placing a further constraint on marketing language for Schedule III products.

DEA extends Schedule III registration to cannabis cultivators, manufacturers and laboratories

The Drug Enforcement Administration has confirmed it will open new registration forms for medical cannabis cultivators, manufacturers, testing laboratories and distributors in the coming weeks, supplementing the dispensary portal that went live on 29 April. As Cannabis Business Times reports, applicants can use the existing Form 225 in the meantime, and businesses that have already submitted applications need not reapply. Registration unlocks federal protections and relief from Section 280E tax rules, which have imposed effective federal rates above 70 per cent on cannabis operators. Broader context on the rescheduling framework is on the Business of Cannabis rescheduling tracker.

ATF proposes firearms form update to recognise medical cannabis’s federally legal status

The Bureau of Alcohol, Tobacco, Firearms and Explosives has proposed revisions to Form 4473, the standard firearms purchase document, to reflect medical cannabis’s reclassification under Schedule III. According to Marijuana Moment, the updated form would remove blanket language barring cannabis consumers from purchasing firearms and distinguish between recreational and medical use instead. The Second Amendment Foundation has expressed support for the change, and rights advocates say the revision brings federal documentation in line with the new legal position. The Justice Department is separately reviewing its defence of laws that prohibit cannabis consumers from owning firearms, though conflicting signals from ongoing DOJ filings suggest broader enforcement reform is not imminent.

Massachusetts lawmakers decline to act on measure to repeal adult-use cannabis sales

A Massachusetts legislative committee has recommended no action on a ballot initiative that would have eliminated the state’s regulated adult-use cannabis market. The Special Joint Committee on Initiative Petitions cited insufficient implementation detail and risks to existing public health safeguards, including product testing standards and youth access controls. As Marijuana Moment reports, the campaign’s organisers must now collect a further 12,429 certified signatures by 1 July to place the question on the November ballot. A parallel legal challenge from cannabis industry participants argues the initiative violates state constitutional protections and impermissibly combines unrelated subjects in a single measure.

Watch this week for the first dedicated DEA registration forms for cannabis manufacturers and laboratories, and monitor whether the Senate takes up the hemp THC provisions left unresolved by the House Farm Bill. The Massachusetts signature deadline on 1 July will be the next indicator of whether the rollback campaign retains sufficient momentum to reach November voters. Stay up to date with all the latest on the Cannabis News Hub.